Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Telix Pharmaceuticals Ltd Share Issue/Capital Change 2024

Jun 26, 2024

31324_rns_2024-06-26_01cc3b0f-181e-4629-9928-a596a7d091f6.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Wednesday June 26, 2024

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued/transferred

Total number of
ASX +security +securities to be
code Security description issued/transferred Issue date
TLXAO SHARE APPRECIATION RIGHTS 144,037 26/06/2024

Refer to next page for full details of the announcement

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

1 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type Registration number ACN 616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

26/6/2024

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

2 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

3 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

TLXAO : SHARE APPRECIATION RIGHTS

Date the +securities the subject of this notification were issued

26/6/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes Were any of the +securities issued to +key management personnel (KMP) or an +associate? Yes Provide details of the KMP or +associates being issued +securities. Name of KMP Name of registered holder Number of +securities Christian Behrenbruch Christian Behrenbruch 144,037 Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms Refer to Telix's 2023 Remuneration Report, within the 2023 Annual Report and to Telix's 2024 Annual General Meeting Notice of Meeting for Performance Share Appreciation Rights valuation methodology, accessible at https://telixpharma.co m/investorcentre/financial-reports-presentations/ Any other information the entity wishes to provide about the +securities the subject of this notification Performance Share Appreciation Rights (notional exercise price $11.94) granted to Managing Director and Group Chief Executive Officer, Christian Behrenbruch, as part of his Target Total Remuneration Package for FY24 following shareholder approval at the Company's AGM held on 22 May 2024. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan Rules, with a measurement period of 2024-2026. For further details, refer to the Remuneration Report in Telix's 2023 Annual Report accessible at https://telixpharma.com/investorcent re/financial-reports-presentations/

Issue details

Number of +securities

144,037

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

4 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

Total number of
ASX +security code and description +securities on issue
TLX : ORDINARY FULLY PAID 334,126,898
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
Total number of
ASX +security code and description +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL 80,000
TLXAR : PERFORMANCE RIGHTS 6,807,720
TLXAP : SHARE RIGHTS 1,230,000
TLXAO : SHARE APPRECIATION RIGHTS 11,356,817
TLXAM : OPTION EXPIRING 20-JUL-2026 EX $5.37 584,492
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL 100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX $4.38 685,510
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS 440,000

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

5 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

14

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

6 / 6